Core Viewpoint - The announcement from Yahui Pharmaceutical (688176.SH) indicates that the Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis has yielded positive preliminary results [1] Group 1: Clinical Trial Results - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor, which increases dopamine levels and decreases norepinephrine levels, restoring intestinal immune homeostasis [1] - The company plans to further evaluate the efficacy of this potential first-in-class therapy in a larger cohort of patients with moderate to severe active ulcerative colitis over a 12-week treatment period [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-031 江苏亚虹医药科技股份有限公司 自愿披露关于 APL-1401 Ⅰb 期临床试验获得积极初 步结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）开展的 APL-1401 用 于治疗中重度活动性溃疡性结肠炎的 Ⅰb 期临床试验（以下简称"该研究"）获 得了积极的初步结果。现就相关情况公告如下： 一、药品基本情况 APL-1401 是公司通过自主研究并发现其全新作用机制用于治疗自身免疫疾 病的口服创新药物。APL-1401 是一种强效、选择性的多巴胺β-羟化酶（DBH） 抑制剂，通过抑制 DBH，从而阻断了多巴胺（DA）合成去甲肾上腺素（NE） 唯一的催化酶，导致 DA 升高、NE 降低，使肠道免疫稳态恢复正常。目前溃疡 性结肠炎（UC）尚无治愈方法，APL-1401 的开发有望给 UC 患者提供新的治疗 手段。 二、该药品研发及其他相关情况 江苏亚虹医药科技股份有限公司董事会 2025 年 8 月 ...

Core Insights - Aihong Pharmaceutical (688176) announced positive preliminary results from its Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis [1] - Based on these positive results, the company plans to further evaluate the potential first-in-class therapy in a larger population of moderate to severe active ulcerative colitis patients over a 12-week treatment period [1] - The aim is to provide more comprehensive supportive evidence for subsequent clinical research, with the goal of offering new treatment options for patients in the future [1]

Core Viewpoint - The company announced positive preliminary results from the Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis (UC) [1] Company Summary - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor that increases dopamine (DA) levels and decreases norepinephrine (NE) levels by inhibiting the only catalytic enzyme for the synthesis of NE from DA [1] - The development of APL-1401 is expected to provide new treatment options for UC patients, as there is currently no cure for ulcerative colitis [1] Industry Summary - Ulcerative colitis (UC) currently lacks a cure, highlighting the significance of APL-1401's potential impact on restoring intestinal immune homeostasis [1]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-030 江苏亚虹医药科技股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第二个 归属期及预留授予部分第一个归属期归属结果暨股份 上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2022 年 7 月 27 日，公司召开第一届董事会第十二次会议，会议审议通 过了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请股 东大会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》。公司独立 董事就本次激励计划相关议案发表了独立意见。 1 同日，公司召开第一届监事会第十次会议，审议通过了《关于公司<2022 年限 制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激 励计划实施考核管理办法>的议案》以及《关于核实公司<2022 年限制性股票激励 ...

Meeting Overview - The shareholders' meeting of Jiangsu Yahon Pharmaceutical Technology Co., Ltd. was held on July 25, 2025, at Wanxin Hotel, Shanghai [1] - A total of 349 ordinary shareholders attended the meeting, representing 200,209,901 voting rights, which accounts for 35.6669% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved, with significant support from ordinary shareholders [1] - For the first proposal, 197,451,292 votes (98.6221%) were in favor, while 1,417,972 votes (0.7082%) were against, and 1,340,637 votes (0.6697%) were abstained [1] - For the second proposal, 197,470,994 votes (98.6319%) were in favor, with 1,241,781 votes (0.6202%) against, and 1,497,126 votes (0.7479%) abstained [1] Legal Compliance - The meeting's convening, procedures, and voting were confirmed to comply with the Company Law of the People's Republic of China and the company's articles of association, ensuring the legality and validity of the voting results [2]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-029 江苏亚虹医药科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 25 日 （二） 股东大会召开的地点：上海市浦东新区高科西路 551 号万信酒店一楼会 议室 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书兼财务负责人出席了本次会议。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 349 | | --- | --- | | 普通股股东人数 | 349 | | 2、出席会议的股东所持有的表决权数量 | 200,209,901 | | 普通股股东所持有表决权数量 | 200,209,901 | | 3、出席会议的 ...

北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 望师事务所 YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会的法律意见书 嘉源(2025)-04-550 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,根据《中华人民共和国公 司法》(以下简称"《公司法》")《上市公司股东会规则》(以下简称"《股东 会规则》")等现行有效的法律、行政法规、部门规章、规范性文件(以下简称 "法律法规")以及《江苏亚虹医药科技股份有限公司章程》(以下简称"《公司 章程》"）的有关规定,指派本所律师对公司 2025年第一次临时股东大会(以 下简称"本次股东大会")进行见证,并依法出具本法律 ...

Core Points - The company is holding a shareholders' meeting to ensure the orderly conduct of the meeting and the rights of shareholders [1][2] - The meeting will include a voting process combining on-site and online methods, with results to be announced afterward [3][5] - The company plans to use remaining raised funds totaling RMB 87.04 million to permanently supplement working capital [11][13] Group 1: Meeting Procedures - Shareholders and their representatives must arrive 30 minutes early for registration and verification of attendance [1] - The meeting will have a structured agenda, allowing shareholders to speak only with the host's permission and within a time limit [2] - Voting will be conducted through both on-site and online methods, with results published in a subsequent announcement [3][5] Group 2: Fund Usage - The company intends to use RMB 87.04 million of the remaining raised funds for working capital, which includes interest income and investment returns [11][13] - The total amount of excess raised funds is RMB 310.73 million, with the proposed usage not exceeding 30% of this total [13][14] - The company assures that this fund usage will not affect the implementation of investment projects and complies with relevant regulations [14]

Core Insights - Yahui Pharmaceutical (688176) is accelerating the review process for its product APL-1702, a photodynamic therapy system for treating high-grade squamous intraepithelial lesions (HSIL), aiming for swift market approval [1] - The company reported a revenue of 202 million yuan in 2024, achieving its commercial operation breakeven target, and a 151.24% year-on-year revenue growth in Q1 2025 [2] - APL-2501, an antibody-drug conjugate for treating various advanced tumors, is progressing well, with plans to complete CMC and GLP toxicology studies in 2025 [2] - APL-2302, a novel oral small molecule inhibitor targeting USP1, has received approval for clinical trials in the US and China, with the first patient enrolled in March 2025 [3] Group 1 - APL-1702 is the first product to show positive results in international Phase III trials for HSIL, with a target population of approximately 2.1 million patients in China [1] - The company is conducting systematic research on market accessibility and payment assurance, and is advocating for policies to support cervical cancer prevention [1] Group 2 - The company has exceeded its initial revenue target for 2024, achieving 202 million yuan, and reported a significant increase in Q1 2025 revenue [2] - APL-2501 has shown superior characteristics compared to competitors, with plans for further development and clinical trial submissions in 2026 [2] Group 3 - APL-2302 is designed to induce synthetic lethality in tumors by inhibiting USP1, with ongoing clinical trials expected to advance in 2025 [3] - The company has received regulatory approvals for APL-2302 trials in both the US and China, indicating strong progress in its clinical development pipeline [3]